RX-5902

11/01/2019 - "The purpose of this study was to evaluate the efficacy of RX-5902 in preclinical models of triple-negative breast cancer (TNBC) and to explore effects on β-catenin expression. "
11/01/2019 - "First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer."
11/04/2020 - "RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer."

11/04/2020 - "These findings indicate that RX-5902 may have important immunomodulatory, as well as anti-tumor activity, in TNBC when combined with a checkpoint inhibitor."
11/01/2019 - "RX-5902 exhibited dose-proportional pharmacokinetics and plasma and tumor tissue in nude mice. "
11/01/2019 - "The activity of RX-5902 was confirmed in vivo in cell line and patient-derived tumor xenograft (PDX) models. "
11/04/2020 - "The addition of RX-5902 to CTLA-4 or PD-1 inhibitors resulted in decreased tumor growth in the 4 T1 and human immune system and MDA-MB-231 xenograft models. "
11/04/2020 - "RX-5902 is a novel anti-cancer agent that inhibits phosphorylated-p68 and thus attenuates nuclear β-catenin signaling. "

11/01/2019 - "RX-5902 treatment resulted in the induction of apoptosis, G2-M cell-cycle arrest, and aneuploidy in a subset of cell lines. "